IDNA vs. FXAIX
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Fidelity 500 Index Fund (FXAIX).
IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. FXAIX is a passively managed fund by Fidelity that tracks the performance of the S&P 500 Index. It was launched on Feb 17, 1988. Both IDNA and FXAIX are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
IDNA vs. FXAIX - Performance Comparison
Loading graphics...
IDNA vs. FXAIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 10.92% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
FXAIX Fidelity 500 Index Fund | -7.05% | 17.84% | 25.01% | 26.29% | -18.14% | 28.71% | 18.42% | 12.90% |
Returns By Period
In the year-to-date period, IDNA achieves a 10.92% return, which is significantly higher than FXAIX's -7.05% return.
IDNA
- 1D
- 4.46%
- 1M
- -6.68%
- YTD
- 10.92%
- 6M
- 23.74%
- 1Y
- 43.65%
- 3Y*
- 8.86%
- 5Y*
- -8.02%
- 10Y*
- —
FXAIX
- 1D
- -0.39%
- 1M
- -7.68%
- YTD
- -7.05%
- 6M
- -4.59%
- 1Y
- 14.42%
- 3Y*
- 17.17%
- 5Y*
- 11.40%
- 10Y*
- 13.75%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. FXAIX - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is higher than FXAIX's 0.02% expense ratio.
Return for Risk
IDNA vs. FXAIX — Risk / Return Rank
IDNA
FXAIX
IDNA vs. FXAIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Fidelity 500 Index Fund (FXAIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IDNA | FXAIX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.58 | 0.84 | +0.74 |
Sortino ratioReturn per unit of downside risk | 2.21 | 1.30 | +0.92 |
Omega ratioGain probability vs. loss probability | 1.26 | 1.20 | +0.06 |
Calmar ratioReturn relative to maximum drawdown | 3.20 | 1.05 | +2.15 |
Martin ratioReturn relative to average drawdown | 10.48 | 5.13 | +5.36 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| IDNA | FXAIX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.58 | 0.84 | +0.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.28 | 0.68 | -0.96 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.77 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.11 | 0.75 | -0.65 |
Correlation
The correlation between IDNA and FXAIX is 0.57, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
IDNA vs. FXAIX - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 1.06%, less than FXAIX's 1.20% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.06% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
FXAIX Fidelity 500 Index Fund | 1.20% | 1.11% | 1.25% | 1.45% | 1.69% | 1.22% | 1.60% | 2.06% | 2.72% | 1.97% | 2.52% | 2.83% |
Drawdowns
IDNA vs. FXAIX - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than FXAIX's maximum drawdown of -33.79%. Use the drawdown chart below to compare losses from any high point for IDNA and FXAIX.
Loading graphics...
Drawdown Indicators
| IDNA | FXAIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.26% | -33.79% | -34.47% |
Max Drawdown (1Y)Largest decline over 1 year | -12.11% | -12.13% | +0.02% |
Max Drawdown (5Y)Largest decline over 5 years | -68.26% | -24.50% | -43.76% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.79% | — |
Current DrawdownCurrent decline from peak | -45.31% | -8.89% | -36.42% |
Average DrawdownAverage peak-to-trough decline | -36.04% | -3.83% | -32.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.83% | 2.50% | +1.33% |
Volatility
IDNA vs. FXAIX - Volatility Comparison
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 10.11% compared to Fidelity 500 Index Fund (FXAIX) at 4.24%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than FXAIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| IDNA | FXAIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.11% | 4.24% | +5.87% |
Volatility (6M)Calculated over the trailing 6-month period | 18.36% | 9.08% | +9.28% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.87% | 18.13% | +9.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.53% | 16.88% | +11.65% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 29.69% | 18.03% | +11.66% |